Search

Author/Creator Kampmann, C.

2. Enzyme replacement therapy for mucopolysaccharidosis VI: long‐term cardiac effects of galsulfase (Naglazyme®) therapy. Issue 2 (5th June 2012)

Authors:
Braunlin, E.; Rosenfeld, H.; Kampmann, C.; Johnson, J.; Beck, M.; Giugliani, R.; Guffon, N.; Ketteridge, D.; Sá Miranda, C. M.; Scarpa, M.; Schwartz, I. V.; Leão Teles, E.; Wraith, J. E.; Barrios, P.; Dias da Silva, E.; Kurio, G.; Richardson, M.; Gildengorin, G.; Hopwood, J. J.; Imperiale, M.
Journal:
Journal of inherited metabolic disease
Issue:
Volume 36:Issue 2(2013)
Page Start:
385
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease. (26th July 2017)

Authors:
Lenders, M.; Oder, D.; Nowak, A.; Canaan‐Kühl, S.; Arash‐Kaps, L.; Drechsler, C.; Schmitz, B.; Nordbeck, P.; Hennermann, J. B.; Kampmann, C.; Reuter, S.; Brand, S.‐M.; Wanner, C.; Brand, E.
Journal:
Journal of internal medicine
Issue:
Volume 282:Number 3(2017)
Page Start:
241
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗